Browse News
Filter News
Found 61 articles
-
Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open
2/9/2024
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced the first peer-reviewed publication of the Phase 3 portion of its pivotal, double-blind, randomized, placebo-controlled Phase 2/3 study (SCORPIO-SR) in patients with mild to moderate COVID-19 in Japan, South Korea and Vietnam in JAMA Network Open.
-
BostonGene Announces Ten Presentations at the 65th American Society of Hematology Annual Meeting & Exposition
12/7/2023
BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced the selection of four abstracts for oral presentation, four abstracts as poster presentations, and two abstracts for online publication at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, California and virtually.
-
Shionogi Presents New Ensitrelvir COVID-19 Data Supporting Effectiveness in Real-World and Clinical Settings at IDWeek 2023
10/11/2023
Shionogi Inc. will present new real-world and clinical data at IDWeek 2023 reinforcing the potential of ensitrelvir, its investigational oral antiviral, to treat the symptoms of COVID-19.
-
BostonGene to Showcase Integrated Approach to Precision Medicine at the 82nd Annual Meeting of the Japanese Cancer Association
9/20/2023
BostonGene, a leading provider of AI-based molecular and immune profiling solutions, announced today that it will participate in the 82nd Annual Meeting of the Japanese Cancer Association (JCA).
-
BostonGene and Hokkaido University Hospital Collaborate to Develop Novel HER2 Protocols for Breast Cancer
9/19/2023
BostonGene today announced an agreement with Hokkaido University Hospital to drive the discovery, validation and implementation of a groundbreaking stratification protocol for HER2-positive breast cancer patients.
-
Shionogi Presents New Ensitrelvir Clinical and Real-World Data Reinforcing Potential Across COVID-19 Populations at ESWI 2023
9/18/2023
Shionogi & Co., Ltd. will present two late-breaking posters at the European Scientific Working Group on Influenza and other Respiratory Viruses’ (ESWI), 9th Influenza Conference.
-
Shionogi Enrolls the First Participant in Japan in its Global Phase 3 Trial of Ensitrelvir for the Prevention of Symptomatic SARS-CoV-2 Infection
6/9/2023
Shionogi & Co., Ltd. today announced the first participant has been enrolled in Japan in its global Phase 3 study, Stopping COVID-19 pRogression with early Protease InhibitOr treatment – Post Exposure Prophylaxis (SCORPIO-PEP).
-
eGenesis Presents New Data on Long-Term Survival in Preclinical Kidney Xenotransplantation at American Transplant Congress 2023
6/5/2023
eGenesis, a biotechnology company developing human-compatible organs for the treatment of organ failure, will present new data during the American Transplant Congress 2023, held June 3 – June 7, 2023 in San Diego, CA.
-
Potential Found to Counter Depression by Restoring Key Brain Rhythm
5/9/2023
Led by researchers from NYU Grossman School of Medicine and University of Szeged in Hungary, a new study in mice and rats found that restoring certain signals in a brain region that processes smells countered depression.
-
Shionogi Receives U.S. FDA Fast Track Designation for Ensitrelvir Fumaric Acid, an Investigational Oral Antiviral for COVID-19
4/4/2023
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for their investigational COVID-19 oral antiviral ensitrelvir (Generic name: ensitrelvir fumaric acid, Code No.: S-217622, hereafter “ensitrelvir”).
-
Priothera cleared to begin Japanese arm of pivotal Phase 3 study with mocravimod in patients with Acute Myeloid Leukemia undergoing allogeneic Hematopoietic Cell Transplant
2/27/2023
Priothera announced that it received clearance from the Pharmaceuticals and Medical Devices Agency in Japan for the pivotal global MO-TRANS Phase 3 study evaluating mocravimod in Acute Myeloid Leukemia patients undergoing allogeneic hematopoietic cell transplant.
-
Shionogi Presents Pivotal Ensitrelvir Fumaric Acid Phase 3 Data and Exploratory Long COVID Data at CROI
2/21/2023
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today, at the 30th Conference on Retroviruses and Opportunistic Infections (CROI), presented further results from the Phase 3 part of the pivotal SCORPIO-SR trial.
-
Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program
2/15/2023
Shionogi & Co., Ltd. announced progress on its comprehensive clinical development program for the novel COVID-19 oral antiviral ensitrelvir.
-
Artificial Tendons and Ligaments Market is Expected To Reach USD 60.90 Billion By 2028 - Reports and Data
9/8/2022
According to the current analysis of Reports and Data, the global artificial tendons and ligaments market was valued at USD 23.16 Billion in 2020 and is expected to reach USD 60.90 Billion by the year 2028, at a CAGR of 13.2%
-
Researchers at Hokkaido University in Japan, in a collaboration with American scientists, may have unlocked the mechanism that drives widespread inflammation in inflammatory diseases.
-
New Data for Shionogi’s COVID-19 Once-Daily Oral Antiviral S-217622 Show Rapid Virus Clearance
4/23/2022
Shionogi & Co., Ltd. announced new results from two late-breaking presentations of S-217622 at the 32nd European Congress of Clinical Microbiology & Infectious Diseases in Lisbon, 23 – 26 April.
-
Shionogi Presents the Results of COVID-19 Therapeutic Agent at ISIRV-WHO Virtual Conference
10/21/2021
Shionogi Presents the Results of COVID-19 Therapeutic Agent at ISIRV-WHO Virtual Conference
-
Asensus Surgical, Inc. Announces Sapporo Medical University Hospital in Japan to Initiate Senhance Robotic Surgery Program
9/29/2021
Asensus Surgical, Inc. today announced Sapporo Medical University Hospital, located in Hokkaido, Japan, has entered into an agreement to lease and utilize a Senhance® Surgical System.
-
Just as it was beginning to appear safe to return to maskless, pre-pandemic life, the Delta variant of the SARS-CoV-2 virus emerged. It is fast-spreading, more likely to lead to hospitalizations, and accounts for most of the breakout infections among fully vaccinated individuals.
-
SanBio Announces Publication of STEMTRA Phase 2 Interim Analysis for SB623 in Neurology
1/5/2021
SanBio Announces Publication of STEMTRA Phase 2 Interim Analysis for SB623 in Neurology Publication Affirms SanBio’s Approach to Treating Chronic Traumatic Brain Injury Patients